Ospemifene (FC-1271a) is a selective estrogen receptor modulator (SERM) approved for treating moderate to severe dyspareunia caused by menopausal vulvovaginal atrophy. It is utilized in research on estrogen receptor pharmacology, with studies demonstrating its tissue-selective agonist/antagonist effects in both in vitro and in vivo models.